We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: May 2017

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials ANN ARBOR, MI – May 17, 2017 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a…

May 17, 2017
Novartis Steps in to Help Seed a Michigan Spinout’s Move into the Clinic with New Eye Drug

Novartis Steps in to Help Seed a Michigan Spinout’s Move into the Clinic with New Eye Drug Endpoints News Novartis has joined hands with some local investors in Michigan to come up with a small but significant $4.25 million A round… Read the Article

May 17, 2017

Month: May 2017

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

Novartis Steps in to Help Seed a Michigan Spinout’s Move into the Clinic with New Eye Drug